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Abstract
The ectodomain of influenza A matrix protein 2 (M2e) is a candidate for a universal influenza A vaccine. We used
recombinant Hepatitis B core antigen to produce virus-like particles presenting M2e (M2e-VLPs). We produced the VLPs with
and without entrapped nucleic acids and compared their immunogenicity and protective efficacy. Immunization of BALB/c
mice with M2e-VLPs containing nucleic acids induced a stronger, Th1-biased antibody response compared to particles
lacking nucleic acids. The former also induced a stronger M2e-specific CD4+ T cell response, as determined by ELISPOT. Mice
vaccinated with alum-adjuvanted M2e-VLPs containing the nucleic acid-binding domain were better protected against
influenza A virus challenge than mice vaccinated with similar particles lacking this domain, as deduced from the loss in body
weight following challenge with X47 (H3N2) or PR/8 virus. Challenge of mice that had been immunized with M2e-VLPs with
or without nucleic acids displayed significantly lower mortality, morbidity and lung virus titers than control-immunized
groups. We conclude that nucleic acids present in M2e-VLPs correlate with improved immune protection.
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Introduction
Human influenza is a highly contagious respiratory disease
caused by influenza A and B viruses, which undergo frequent
antigenic changes. Few infections are as detrimental as influenza in
terms of school and work absenteeism, medical consultation load,
hospitalization, and death toll [1]. Seasonal influenza is currently
counteracted by vaccination with a tri- or quadrivalent vaccine
based on the hemagglutinin antigen, which is highly variable.
Therefore, the composition of the influenza vaccine is adapted
nearly every year so that it corresponds as much as possible to the
antigenicity of the strains expected to circulate during the
upcoming season [2]. The World Health Organization conducts
continuous global surveillance of new influenza virus strains and
guides the annual updating of the vaccines [3].
Human influenza pandemics are associated with the introduc-
tion of a novel hemagglutinin subtype or a hemagglutinin that is
antigenically very different from the circulating epidemic strains.
Pandemic outbreaks are unpredictable, and the Mexican flu
pandemic in 2009 caused by an H1N1 virus of swine origin
certainly took the world by surprise [4]. The impact of
H1N1pdm2009 on human health during its first year of
circulation was somewhat milder than that caused by most
seasonal H3N2 influenza viruses. However, most fatal cases
associated with the H1N1pdm2009 virus occurred in young
people, which is unusual for seasonal flu [5,6].
Seasonal influenza vaccines offer little if any protection against
a pandemic virus. In 2009, it took six months before a monovalent
H1N1pdm2009 vaccine could be distributed: in other words, it
became available only after the first wave of the pandemic virus
attack [7]. Different approaches are being followed to develop
influenza vaccines with broadened immune protection in order to
control pandemic influenza outbreaks more efficiently. For
example, attempts to introduce antibody-based immunity directed
against conserved parts of the hemagglutinin have met this goal
with some success [8,9,10]. Other universal influenza vaccine
candidates are based on the induction of broadly reactive T-cell
responses [11,12,13]. We and others have focused on the
development of a recombinant protein vaccine based on the
conserved, extracellular domain of the influenza A matrix protein
2 (M2e) linked to a carrier [14,15,16,17,18].
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M2 is an integral membrane protein of 97 amino acid residues.
It is scarce on virus particles but abundant on virus-infected cells
[19,20]. It self-assembles as a homo-tetramer into a proton-
selective ion channel [21]. During budding, M2 also changes the
cell membrane curvature and promotes membrane scission and
hence release of newly formed virions [22]. M2e is the amino-
terminal extracellular part of M2 and consists of 23 amino acid
residues. It is minimally immunogenic during infection and
following conventional vaccination [23]. This might partially
explain its remarkable sequence conservation across all human
influenza A strains [24]. In addition, the coding information for
M2e overlaps with the open reading frame of M1. This imposes
a genetic constraint that limits the tolerance for mutations in M2e
[25].
We fused M2e to the Hepatitis B virus core capsomer (HBc) to
produce recombinant virus-like particles (VLPs). These VLPs,
which display M2e on their surface at high density, are highly
immunogenic and induce protection against the death and
morbidity caused by challenge with influenza A virus [16,26].
Induction of protection against multiple HA-subtypes of influenza
by M2e vaccines has been confirmed by using various carrier
conjugates fused chemically or genetically and in both mouse and
ferret models [15,27,28,29,30]. Protection induced by immuniza-
tion with M2e-fusion constructs against experimental challenge is
largely dependent on antibodies directed against M2e, although
a contribution of an MHC class-II-restricted CD4+ T-cell epitope
in M2e is likely also involved [16,31]. Antibodies directed against
M2e lack virus-neutralizing activity. Instead, protection by M2e-
specific IgG antibodies relies on Fc receptors and innate immune
cells such as macrophages and natural killer cells [32,33,34].
Interestingly, and in line with the infection-permissive nature of
M2e-based vaccines, exposure of M2e-immune mice to influenza
A virus infection is compatible with the induction of cross-reactive
T cells [35].
HBc-fusions are frequently used to present weakly immunogenic
determinants to the immune system. HBc is a powerful immuno-
gen that functions as both a T-cell-dependent and a T-cell-
independent antigen [36] and can induce strong humoral [37], T
helper (Th) [38] and even cytotoxic T cell (CTL) responses [39].
The HBc gene can be expressed efficiently in Escherichia coli, and
VLPs produced in this way are indistinguishable by electron
microscopy and physico-chemical analyses from HBc particles
produced by virally infected liver cells [40]. In-frame insertions of
heterologous epitopes in the HBc subunit at the DNA level usually
do not interfere with VLP formation, and these epitopes can be
displayed as a dense, highly immunogenic constellation [41]. The
HBc capsomer contains a carboxy-terminal nucleic acid binding
domain that is important for the encapsidation of the HB virus
genome [42]. During recombinant expression and VLP assembly
of HBc capsomers in E. coli, RNA from the bacterial host is also
incorporated within VLPs. This incorporated prokaryotic RNA
can act as an adjuvant to prime Th1 immunity directed against the
HBc antigen [43].
Here, we compared the immunogenicity and protective efficacy
of M2e-VLPs containing or lacking part of the nucleic acid
binding domain of HBc. We demonstrate that in the presence of
this domain, VLPs with or without the amino-terminal M2e fusion
contain nucleic acids derived from the E. coli host. In addition,
immunization of BALB/c mice with M2e-VLPs containing nucleic
acids resulted in a higher M2e-specific serum IgG2a response as
well as higher IFNc responses in splenocytes. Although immuni-
zation of mice with M2e-VLPs (whether lacking or containing
nucleic acids) protected against a lethal challenge with mouse-
adapted X47 (H3N2) virus or PR/8 virus, protection against
weight loss was significantly improved by the presence of
entrapped RNA. We conclude that nucleic acids entrapped within
M2e-VLPs improve protection against the morbidity caused by
influenza A virus challenge.
Materials and Methods
2.1. Preparation and Analysis of Recombinant HBc VLPs
All VLPs were produced in and purified from E. coli. The VLPs
used in this study are shown schematically in Figure 1A. VLP-
1123 (M2e2/RNA-) and VLP-1818 (M2e+/RNA-) have been
described [44]. VLP-1123 was derived from a truncated HBc gene
coding for amino acids 1–149 followed by a cysteine residue. VLP-
1818 contains three tandem copies of M2e fused to the N-terminus
of VLP-1123. The N-terminal M2e copy in VLP-1818 retains the
initiator methionine. In the first and second copy of M2e, the
cysteines at positions 17 and 19 are mutated to serines, whereas
the third M2e copy retains its cysteines. VLP-1632 (M2e2/
RNA+) and VLP-1965 (M2e+/RNA+) are similar to VLP-1123
and VLP-1818, respectively, except that the HBc carrier consists
of amino acids 1–163 followed by a cysteine residue. Therefore,
VLP-1632 and VLP-1965 contain part of the arginine-rich
carboxy-terminal domain of HBc.
All VLPs were expressed from a modified pKK223-3 plasmid
(Amersham Pharmacia, UK) [44] and purified as described
previously [45]. Briefly, overnight cultures of E. coli TB1
transformed with the respective expression vectors were harvested
by centrifugation and lysed in Tris-EDTA buffer (50 mM Tris-
HCl, 10 mM EDTA, pH 8.0) using a French press (Thermo-
Spectronic, Cambridge, United Kingdom). Proteins in the cleared
lysate were precipitated with ammonium sulfate and the pre-
cipitate was resuspended in Tris-EDTA buffer (50 mM Tris-HCl,
10 mM EDTA, pH 8.0). Recombinant particles were purified
from the dialyzed ammonium sulfate fraction by gel filtration
chromatography on a Sepharose CL-4B column (Pharmacia,
Piscataway, N.J.), followed by hydroxyapatite chromatography
(Clarkson, South Williamsport, Pa.) and anion-exchange on
a Mono-Q (Pharmacia). Purified VLPs were dialyzed against
20 mM sodium phosphate, pH 6.8, and the protein concentration
was determined using a standard bicinchoninic acid assay (Pierce).
The efficiency of particle formation and the presence of particle-
bound nucleic acids were analyzed by agarose gel electrophoresis.
VLPs (10 mg) were loaded on a 2% agarose gel and run for 2 h at
80 V in TAE buffer. The gel was stained with ethidium bromide
to reveal nucleic acids and with Coomassie brilliant blue to reveal
proteins. In addition, 2 mg of each VLP was boiled for 5 min in
reducing Laemmli sample buffer, separated by SDS-PAGE, and
stained with Coomassie brilliant blue.
Nucleic acids from 40 mg VLP-1632 were isolated using the
NucleoSpin RNA Virus kit (Macherey-Nagel) according to
manufactures recommendations, including the optional proteinase
K treatment but without addition of carrier RNA. Total cellular
RNA was isolated from HEK293T cells using by the use of
RNeasy kit (Qiagen, Hilden, Germany). One mg of purified VLP-
1632 nucleic acids, cellular RNA, miniprep plasmid DNA, as well
as control plasmid mini prep DNA that was additionally submitted
to the procedures used for the isolation of the VLP nucleic acids
were treated with either PBS, 5 mg RNase from bovine pancreas
(Sigma-Aldrich, St. Louis, USA) or 1.4 Kunitz of DNAse I
(Qiagen) for 30 minutes at 25uC. The samples were then analysed
by agarose gel electrophoresis followed by SYBR Safe staining.
The LPS-content of different VLP preparations was determined
using the Toxinsensor Chromogenic LAL Endotoxin Assay Kit
(GenScript, NJ, USA) according to the manufacturer’s instruc-
M2e-VLPs with Improved Protection
PLOS ONE | www.plosone.org 2 March 2013 | Volume 8 | Issue 3 | e59081
tions. Briefly, a standard curve was generated from a two-fold
dilution series of E. coli endotoxin standard in LAL reagent water
(1 EU –0.125 EU). Two-fold dilution series of VLPs were made in
LAL reagent water and assayed along with the standard and
a blank control. After 10 min incubation at 37uC of samples and
controls with LAL (Limulus Amebocyte Lysate), and at the end of
the reactions absorption was measured spectrophotometrically at
545 nm, using LAL reagent water as a blank. Endotoxin contents
in VLP preparation were calculated using the standard curve and
expressed as EU/mL or EU/mg of protein.
2.2. Mouse Vaccination and Challenge
All mouse experiments were conducted according to the
national (Belgian Law 14/08/1986 and 22/12/2003, Belgian
Royal Decree 06/04/2010) and European (EU Directives 2010/
63/EU, 86/609/EEG) animal regulations. Animal protocols were
Figure 1. The C-terminal arginine-rich domain of recombinant HBc-based VLPs binds nucleic acids. A. Schematic representation of the
recombinant M2e-VLPs and control VLPs used in this study. Light grey boxes on the left in VLP-1818 and VLP-1965 represent three tandem M2e
copies; white boxes represent HBc amino acid residues 1–149; dark grey boxes on the right in VLP-1965 and VLP-1632 represent part of the arginine-
rich domain of HBc (residues 150–163). In all constructs, a C-terminal cysteine residue (cys) was engineered to improve particle stability. B. Native
agarose gel analysis of VLPs, followed by staining with Coomassie Brilliant blue (left) or ethidium bromide (right). C. Purified recombinant VLPs (2 mg
each) were separated by SDS-PAGE and stained with Coomassie Brilliant Blue. D. VLP-1632 contains RNA. One mg of nucleic acids purified from VLP-
1632, similarly purified plasmid DNA, plasmid DNA and total mammalian cellular RNA were treated with either PBS, RNAse or DNAse and analyzed by
agarose gel electrophoresis followed by SYBR Safe staining. Numbers on the left indicate sizes in base pairs of the DNA marker in the left hand lane.
doi:10.1371/journal.pone.0059081.g001
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approved by the ethics committee of Ghent University (permit
number LA1400091, approval ID 2010/001). All efforts were
made to minimize the suffering of the animals. Specific-pathogen-
free female BALB/c mice were obtained from Charles River
(France) and immunized at the age of eight weeks. The animals
were housed in a temperature-controlled room (biosafety level 2)
with 14/10-h light/dark cycles and received food and water ad
libitum.
Figure 2. VLPs containing nucleic acids promote a Th1-polarized humoral immune response. A. Three groups of 16 BALB/c mice were
immunized twice intraperitonealy with 10 mg of VLP-1123, VLP-1818 or VLP-1965, without adjuvant. Priming and boosting injections were given at
three week intervals. Two weeks after the boost, M2e-specific serum IgG1 and IgG2a titers were determined by M2e peptide ELISA. White and black
bars: serum samples after priming and boosting, respectively. IgG1/IgG2a ratios were calculated by dividing the mean of the IgG1 endpoint titers by
the mean of the IgG2a endpoint titers, and are shown on the right. (*: P,0.05, **: P,0.01 two-sample t-test). B. The particles were adjuvanted with
Alhydrogel and used to immunize BALB/c mice (14 per group, 10 mg of VLP i.p. per animal). Two weeks after priming, M2e-specific (left) and HBc-
specific (right) IgG1 and IgG2a titers were determined in sera pooled from the 14 mice. C. Groups of 12 BALB/c mice were immunized twice by i.p.
injection of 10 mg of VLP-1123, VLP-1623, VLP-1818 or VLP-1965 formulated with Alhydrogel. Priming and boosting injections were three weeks apart.
M2e-specific serum IgG1 and IgG2a titers are shown in the top panels and HBc-specific titers in the bottom panels. White and black bars: serum
samples two weeks after priming and boosting, respectively. (*: P,0.05, **: P,0.01, ***: P,0.001, two-sample t-test). Bars in A and C represent
averages and error bars represent standard error of the mean. #: titer lower than 100.
doi:10.1371/journal.pone.0059081.g002
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M2e-VLPs or control VLPs (10 mg each) were used without
adjuvant or adjuvanted with Alhydrogel (Brenntag Biosector A/S
Fredrikssund, Denmark) and injected intraperitoneally (i.p.).
Particles were adsorbed using a 10% (v/v) solution of a 2.0%
Alhydrogel stock solution prior to injection. Mice were primed and
boosted at intervals of two or three weeks as indicated in the figure
legends. To evaluate the protective efficacy of the vaccine, mice
were challenged with 4 LD50 of mouse-adapted X47 (H3N2) virus
or with 4 LD50 of PR/8 virus, as indicated in the figure legends.
The mice were anesthetized by i.p. injection of a mixture of
ketamine (12 mg/kg) and xylazine (60 mg/kg). Survival and body
weight were monitored for 14 days after challenge.
2.3. Determination of Serum Antibody Levels and M2e-
specific Cellular Responses
Two weeks after each immunization, blood samples were
collected from the lateral tail vein. Blood was allowed to clot for
30 min at 37uC, and serum was obtained by combining the
supernatants from two successive centrifugations. The titers of
M2e- specific antibodies and of IgG subclasses in the serum were
determined by ELISA in 96-well Maxisorp immuno-plates (Nunc,
Roskilde, Denmark) coated overnight with M2e peptide (2 mg/ml
in carbonate buffer, 50 ml/well, 37uC). After coating, plates were
washed twice with PBS +0.1% Tween 20 and blocked with 3%
milk in PBS. Next, three-fold serial dilutions of mouse serum,
starting with a 1/100 dilution, were dispensed in the wells and
incubated for 1 h. Sheep-derived anti-mouse serum conjugated
with horseradish peroxidase (GE Healthcare UK Ltd, Chalfont St.
Giles, U.K.), horseradish peroxidase-conjugated Abs specific for
mouse isotypes IgG1 or IgG2a (Southern Biotechnology Associ-
ates, Birmingham, AL) and tetramethylbenzidine substrate (Sig-
ma–Aldrich) were used to determine specific antibody titers.
Antibody titers are defined as the reciprocal of the highest dilution
with an OD450 that is at least double the OD450 of preimmune
serum samples. HBc-specific antibodies were determined using
a sandwich ELISA as described [44].
M2e-specific T cell responses were evaluated by measuring
interferon-c (IFN-c) by enzyme-linked immunospot (ELISPOT).
This analysis was done on splenocytes from mice that had been
immunized twice two weeks apart by i.p. injection of Alhydrogel-
adjuvanted VLP-1123, VLP-1632, VLP-1818, VLP-1965 or PBS.
ELISPOT plates were purchased from U-Cytech Biosciences
(Utrecht, The Netherlands) and used according to the manufac-
turer’s protocol. Briefly, 96-well immunoplates were coated with
monoclonal anti-IFN-c antibodies and blocked with blocking
buffer. Fourteen days after the second immunization, and six days
after challenge with 4 LD50 of X47 virus, the spleens of five mice
per group were isolated aseptically and single-cell suspensions were
prepared. After lysis of red blood cells with ammonium buffer,
36105 splenocytes were plated in 100 ml of culture medium
supplemented with 4 mg/ml of HPLC-purified peptide for
restimulation. Splenocytes from each mouse were analyzed in
triplicate. The M2e-specific peptide was SLLTEVETPIR-
NEWGCRCNDSSD (M2e), and the negative control peptide
was MNNATFNYTNVNPISHIR. For ELISPOT analysis of
splenocytes isolated six days after challenge, nucleoprotein-specific
responses were determined by restimulation with the H2d-
restricted NP-derived TYQRTRALV peptide. After 16 h of
peptide restimulation, plates were washed with ELISA wash
buffer and IFN-c trapped on the plates was detected by
a biotinylated polyclonal anti-IFN-c antiserum. Subsequent in-
cubation with GABA-conjugated streptavidin was used to develop
silver spots at places were immune cells secreted IFN-c during
peptide restimulation. Splenocytes from each mouse were
analyzed in triplicate and the spots were counted using an
inverted light microscope.
2.4. Bone-marrow Derived Dendritic Cell (BMDC)
Isolation, Stimulation and RT-qPCR Analysis
Bone-marrow was isolated by flushing the tibia and the femur of
WT, MyD882/2 and TRIF2/2 mice (all in the Bl/6 background)
with ice-cold PBS. After lysing red blood cells with ACK red blood
cell lysis buffer (BioWhittaker, Wakersville, MD, USA), 3.5 x 106
bone marrow cells were seeded in petri dishes and cultured for 8
days in 10 ml RPMI 1640 (Invitrogen, Merelbeke, Belgium)
supplemented with 10% fetal calf serum and 20 ng/ml GM-CSF
(Peprotech, Londen, UK). Medium was replenished every 3 days.
On day 8, 1 x 106 immature dendritic cells were stimulated with
20 mg of VLP-1123, VLP-1632, VLP-1818, VLP-1965 or 1 mg
ODN 1826 (Invivogen, San Diego, CA) for 20 h. RNA was
isolated by using the RNeasy Plus Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol. cDNA was
synthesized using a Superscript II Reverse Transcription Reagent
Kit (Invitrogen, Merelbeke, Belgium). Real-time quantitative PCR
(qPCR) was performed on a Lightcycler 480 using a qPCR kit for
SYBR Green I (both Roche Diagnostics, Mannheim, Germany).
Real-time qPCR amplification was performed in triplicate
reactions. mRPL13a mRNA was used as a reference housekeeping
gene for normalization. All primers were purchased from
Invitrogen. The PCR conditions were as follows: preincubation
at 95uC for 5min; 50 cycles at 95uC for 10s and at 60uC for 30s.
The following forward and reverse primers were used: 59-
TAGTCCTTCCTACCCCATTTCC-39 and 59-
TTGGTCCTTAGCCACTCCTTC-39 (murine il6); 59-CACCT-
CACAAGCAGAGCACAAG-39 and 59- GCATTAGAAA-
CAGTCCAGCCCATAC-39 (murine il1b); 59-
CCTGCTGCTCTCAAGGTTGTT-39 and 59-
TGGCTGTCACTGCCTGGTACTT-39 (murine rpl13a).
Figure 3. VLPs with nucleic acids promote a Th1-polarized
cellular immune response. BALB/c mice (n = 23 per group) were
immunized twice by i.p. injection of 10 mg of VLP-1123, VLP-1623, VLP-
1818 or VLP-1965 formulated with Alhydrogel. An additional control
group received PBS with Alhydrogel (PBS). Priming and boosting
injections were two weeks apart. Two weeks after the boost,
splenocytes were isolated from five mice in each group and analyzed
in triplicate for each mouse. Following 16 h of in vitro stimulation of
splenocytes with M2e peptide, IFN-c secreting cells were quantified by
ELISPOT analysis. Results are shown as the average number of spots per
300,000 splenocytes. Bars represent averages with error bars depicting
the standard error of the mean (*:P,0.001 two-sample t-test). #: less
than 10 spots.
doi:10.1371/journal.pone.0059081.g003
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2.5. Determination of Lung Virus Titers
Three to five mice from each group were killed by cervical
dislocation four or six days after challenge. The lungs were
removed aseptically and homogenized in 1 ml of sterile, ice-cold
PBS. The extracts were transferred to centrifuge tubes and cell
debris was pelleted for 10 min at 400 g and 4uC. The titers of
infectious virus were determined in triplicate by titration of the
cleared lung extracts on MDCK cells. Briefly, monolayers of cells
were infected for 1 h with 50 ml of serial 1:10 dilutions of the lung
homogenates in a 96-well plate in serum-free DMEM medium
containing penicillin and streptomycin (Invitrogen). Following
infection, the medium was replaced by medium containing 2 mg/
ml of TPCK-treated trypsin (Sigma-Aldrich, Germany). Endpoint
virus titers were determined after four days, as described by Reed
and Muench, by interpolating the dilution that infected 50% of the
wells, as determined by the presence of chicken red blood cell
hemagglutinating activity in the supernatants.
Figure 4. VLP-associated nucleic acids signal through MYD88 and TRIF. RT-qPCR was used to analyze mRNA expression levels of the pro-
inflammatory cytokines IL-1b and IL-6 20 hours after stimulation of WT, MyD882/2 or TRIF2/2 DCs with 20 mg of VLP-1123, VLP-1632, VLP-1818, VLP-
1965 or 1 mg of ODN 1826. Results represent mean n-fold induction levels compared to unstimulated control cells6 SD from triplicate PCR reactions.
doi:10.1371/journal.pone.0059081.g004
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2.6. Histopathology
Four days after challenge, mice were euthanized by cervical
dislocation and samples of the apical, median and caudal regions
of the lungs (bilateral) were removed, fixed in 4% paraformalde-
hyde, embedded in paraffin wax, sectioned at 5 mm, and stained
with hematoxylin-eosin. Slides were examined in a blinded fashion
using an Olympus BX 50 microscope and micrographs were
made.
2.7. Statistical Analysis
Comparison of antibody titers between two groups was done
with the two-tailed Student’s t-test. Survival rates were plotted as
Kaplan-Meier curves and analyzed with the log-rank test.
Morbidity parameters after infection of more than two groups
were compared using the Holm-Sidak method. Statistical analyses
were performed with Graphpad Prism version 4.00 for Windows
(GraphPad Software, San Diego California, www.graphpad.com)
and with the R language and environment for statistical
computing, R Development Core Team, 2009 (R Foundation
for Statistical Computing, Vienna, Austria (ISBN 3-900051-07-0,
www.R-project.org).
Results
In vitro Characterization of M2e-VLPs Containing or
Lacking Bound Nucleic Acids
Previously, we reported on the characterization and immuno-
protective efficacy of M2e-VLPs produced by the HBc pre-
sentation technology [16,44]. In these studies we used HBc VLPs
that either contained or lacked the carboxy-terminal arginine-rich
domain of HBc. This domain is responsible for nucleic acid
binding and was shown to prime the mammalian immune
response towards a Th1 response because it facilitates the
incorporation of RNA within the HBc-based VLP [43]. Such
a Th1 response is favorable for anti-M2e mediated protection
[32,44]. To investigate if HBc VLPs containing the carboxy-
terminal arginine-rich domain can induce a more favorable M2e
immune response than HBc VLPs lacking this domain, we
constructed M2e-presenting HBc VLPs and corresponding control
VLPs. The carboxy-terminal arginine-rich domain was either
included [VLP-1965 (M2e+/RNA+) and VLP-1632 (M2e2/
RNA+)] or excluded [VLP-1818 (M2e+/RNA2) and VLP-1123
(M2e2/RNA2)] (Figure 1A). SDS-PAGE analysis demonstrated
that the purified particles were composed of subunits of the
expected molecular weight (Figure 1C). In native agarose gel
electrophoresis, all VLPs migrated predominantly as single bands,
confirming their uniform particulate nature [46] (Figure 1B, left
panel). As expected, co-migrating nucleic acids, revealed by
ethidium bromide staining, were clearly detectable only in VLP-
1965 and in the corresponding control particle VLP-1632, both of
which harbour the nucleic acid binding domain (Figure 1B, right
panel). Incubation of the particles at 25uC for one hour with
RNase or DNase failed to remove the nucleic acids, suggesting
that the nucleic acids were trapped within the VLPs and hence
protected from exogenous nucleases under these conditions (data
not shown). Therefore, we isolated the nucleic acids from VLP-
1632 particles by proteinase K treatment followed by silica
membrane-based purification. These purified nucleic acids derived
from VLP-1632 were susceptible to RNAse and resistant to
DNAse treatment (Figure 1D). We conclude that extending the
HBc capsid protein at its amino-terminal end with multiple copies
of M2e affects neither VLP formation nor the nucleic acid (most
likely RNA) binding capacity of these VLPs.
Nucleic Acids Bound to M2e-VLPs Correlates with a Th1-
polarized Humoral Immune Response
We next compared the immunogenicity of the VLP types.
BALB/c mice (n = 16 per group) were immunized by i.p. injection
of 10 mg of unsubstituted control VLPs, VLP-1818 or VLP-1965.
In the absence of added adjuvant, the M2e-specific IgG1 titers in
serum were significantly lower in mice that had been immunized
with VLP-1965 than in VLP-1818 immunized mice. Conversely,
M2e-specific IgG2a titers were significantly higher in mice
immunized with VLP-1965 compared to VLP-1818 vaccine
recipients, and this was true after both priming and boosting
(Figure 2A).
Adjuvants promote the immunogenicity of M2e-fusion con-
structs [16]. The alum-based adjuvant Alhydrogel is suitable for
human use and we previously reported that this adjuvant enhances
the immunogenicity of M2e-VLPs carrying a single M2e epitope
[44]. Therefore, we also analyzed the effect on immunogenicity of
the particle-associated nucleic acids when these particles were
formulated with Alhydrogel. To be able to compare our results
with those of Riedl et al., who used a single immunization without
adjuvant [43], we analyzed M2e- and HBc-specific antibodies two
weeks after priming in groups of 14 BALB/c mice. In this
experiment, the IgG1 titers were lower for alum-adjuvanted
particles containing bound nucleic acids (VLP-1632 and -1965)
than for those lacking it (VLP-1123 and -1818). In contrast, serum
IgG2a titers against M2e and against the carrier were clearly
higher in recipients of alum-adjuvanted VLPs with associated
nucleic acids (Figure 2B).
We next performed an independent prime-boost experiment
with alum-adjuvanted particles. M2e-specific serum IgG2a
responses were higher following vaccination with VLP-1965 than
following VLP-1818 (Fig. 2C). Likewise, significantly lower IgG1
and higher serum IgG2a titers directed against the HBc carrier
were apparent when nucleic acid-containing VLPs were used,
which was observed for the unsubstituted particles (VLP-1123
compared to VLP-1632) after prime and boost and only after the
boost immunization for the M2e-displaying particles VLP-1818
and VLP-1965 (Fig. 2C).
M2e contains an MHC-II-restricted T cell epitope that can
contribute to immune protection in the BALB/c mouse model
[31]. Therefore, we used IFN-c ELISPOT to compare the
magnitude of the M2e-specific T helper cell responses. Mice that
had been immunized with VLP-1965 displayed a significantly
stronger splenic Th1 response upon in vitro restimulation with M2e
peptide than mice immunized with VLP-1818 recipient mice
(Fig. 3).
From these results we conclude that extending VLPs with part
of the carboxy-terminal nucleic-acid-binding domain of the HBc
Table 1. Characteristics of virus-like particles used in this
study.
VLP Make-up EU/ml* EU/mg of protein*
VLP-1123 M2e2/RNA2 2485 2,16
VLP-1632 M2e2/RNA+ 50880 46,26
VLP-1818 M2e+/RNA- 250022 320,54
VLP-1965 M2e+/RNA+ 7840 18,67
*LPS-content per ml of VLP solution or per mg of protein, expressed as
international units and as determined by the LAL-assay.
doi:10.1371/journal.pone.0059081.t001
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Figure 5. Immunization with VLP-1965 provides better protection against morbidity caused by influenza A virus challenge than
VLP-1818. A. Groups of 12 BALB/c mice were immunized twice with an interval of three weeks with 10 mg of the indicated VLPs, adjuvanted with
Alhydrogel. Three weeks after the second immunization, mice were challenged with 4 LD50 of mouse-adapted X47 virus. Survival rate (left; P,0.001,
Kaplan Meier test) and body weight (right; P,0.05, two-sample t-test on days 6 and 7 after challenge) were monitored for two weeks starting from
the day of challenge. B. Groups of 8 (PBS), 12 (VLP-1818) or 13 (VLP-1965, -1632 and -1123) BALB/c mice were immunized twice with a two-week
interval with 10 mg of the indicated VLPs, adjuvanted with Alhydrogel. One group of mice received PBS with Alhydrogel (PBS). Two weeks after the
second immunization, mice were challenged with 4 LD50 of mouse-adapted X47 virus. Survival rate (left; P,0.001, Kaplan Meier test) and body weight
(right; P,0.05, two-sample t-test on days 6 after challenge) C. Groups of 14 BALB/c mice were immunized three times with three-week intervals by
i.p. injection of 10 mg of VLP-1123, VLP-1818 or VLP-1965, adjuvanted with Alhydrogel. Three weeks after the second boost, mice were challenged
with 4 LD50 of PR/8 virus. Survival rate (left; P,0.0001) and body weight (right; P,0.05 on days 8, 10 and 12 after challenge).
doi:10.1371/journal.pone.0059081.g005
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capsomer correlates with a Th1 type of immune response in
BALB/c mice.
MYD88 and TRIF are Involved in Gene Induction by HBc-
based VLPs
Toll-like receptors (TLRs) are vital components of the
mammalian innate immune system. They recognize microbial
molecular patterns such as double-stranded RNA, 59 uncapped
RNA, CpG DNA, and LPS. Engagement of TLRs by their
cognate ligands results in the induction of type I IFN and
inflammatory cytokine genes. This TLR-dependent gene activa-
tion depends on the adaptor proteins myeloid differentiation
primary response protein 88 (MyD88) and TIR domain-contain-
ing adapter inducing IFNb (TRIF) and may promote a subsequent
adaptive immune response [47]. To obtain some mechanistic
insights in the contribution of these adapter proteins to the
immunogenic profile of the VLPs used in this study, we compared
the expression levels of the pro-inflammatory genes IL-6 and IL-
1b in BMDCs derived from TRIF2/2, MyD882/2 and WT mice
stimulated with 20 mg of VLP-1123, VLP-1632, VLP-1818 or
VLP-1965. As a control, BMDCs were incubated with the TLR-9
agonist ODN 1826 which signals through MyD88. MyD88
deficiency evoked a strong decrease in the expression level of IL-
1b and completely blocked the induction of IL-6. In TRIF2/2
DCs, expression of IL-6 was profoundly downregulated while the
decrease in IL-1b expression was more modest (Fig. 4). Compar-
ison of the LPS content of the E. coli-derived recombinant VLPs,
revealed a variable level with the lowest amount found in VLP-
1123 and VLP-1965 and more significant amounts in VLP-1632
and VLP-1818 (Table 1). Taken together, we found no clear
correlation between LPS-content, RNA-content and MyD88- or
Trif-dependent gene induction from these in vitro BMDC stimu-
lation assays. It is possible that the contribution of the RNA-
contained in VLP-1632 and VLP-1965 was masked by LPS or
other microbial-derived TLR agonists.
Incorporation of Nucleic Acids in VLPs Improves
Protection by M2e-VLPs Vaccination
We next compared the protective efficacy of VLP-1818 and
VLP-1965 particles. M2e-immune mice survive a lethal influenza
A virus challenge but they usually lose some weight. The extent of
weight loss in M2e-immune mice depends on the adjuvant, route
of immunization and antibody isotype [48]. In BALB/c mice,
IgG2a antibodies directed against M2e protect better than their
IgG1 counterpart [32]. In independent immunization experiments
we consistently noticed significantly higher M2e-specific IgG2a
antibody titers in serum of mice that had been primed and boosted
with VLP-1965 particles containing nucleic acids than mice that
received VLP-1818 (Fig. 2). Because we previously found that
immunization with VLP-1818 protected against a potentially
lethal challenge with influenza A virus [44], we anticipated that it
would require a very large number of mice to obtain a significant
difference in survival outcome when applying this parameter as
a read out. Therefore, we focused on body weight drop to
compare protective efficacy following challenge and we did so in
independent experiments. This comparison of efficacy between
VLP-1818 and VLP-1965 was important because its outcome
would help to guide the choice of the lead M2e-VLP vaccine
candidate for a Phase I clinical study.
First, we vaccinated groups of 12 BALB/c mice twice three
weeks apart with 10 mg of the VLPs in the presence of Alhydrogel.
Three weeks after the boost, mice were challenged with 4 LD50 of
mouse-adapted X47 virus, and morbidity and mortality were
monitored. All mice immunized with VLP-1818 or VLP-1965,
except for one in the VLP-1818 group, survived the challenge.
Morbidity after challenge was most severe in mice immunized with
control VLP-1123 or VLP-1632 and all animals in these groups
died after challenge (Figure 5A). Interestingly, during the peak
days of morbidity following challenge, VLP-1965-immunized mice
lost significantly less body weight than mice immunized with VLP-
1818 (Figure 5A).
In an independent second experiment, we compared the
protective efficacy in groups of BALB/c mice that had been
immunized twice with 10 mg of control or M2e-substituted VLPs.
Alhydrogel was used as adjuvant, a PBS-Alhydrogel group was
also included and priming and booster immunizations were two
weeks apart. Two weeks after the booster immunization, mice
were challenged with 4 LD50 of mouse-adapted X47 virus and
monitored for survival and morbidity. Following challenge, all
mice in the control groups gradually lost weight and eventually
died or had to be euthanized. In contrast, all VLP-1965 and all
except one VLP-1818 immunized mice survived the challenge
(Figure 5B). Body weight loss was again higher in the VLP-1818
group and differed significantly from that of the VLP-1965 mice
on day 6 after challenge (Figure 5B).
Finally, we also compared the effect of an additional boost
vaccination on control of morbidity, between Alhydrogel-adju-
vanted VLP-1818 and VLP-1965 vaccines. Groups of 14 mice
were used and challenge was with PR/8 virus, which is highly
virulent to mice [49]. All VLP-1123 immunized mice died after
infection whereas M2e-immunized survived. Again, VLP-1965-
immunized mice experienced significantly less body weight loss
than mice immunized with VLP-1818 (Figure 5C). In summary,
mice vaccinated with VLP-1965 or VLP-1818 survived a poten-
tially lethal influenza A virus challenge. In addition, VLP-1965
was more protective than VLP-1818 against morbidity caused by
challenge.
Lung Virus Load is Reduced in M2e-immune Mice
In the aforementioned challenge experiments, we also de-
termined the lung virus load. Three to five mice from each group
were sacrificed on day 4 or 6 after challenge. We consistently
observed a one to two log lower virus load in VLP-1818 and VLP-
1965 immunized mice compared to control groups. As an
example, Figure 6 depicts the lung virus loads in mice that had
Figure 6. Immunization with M2e-VLPs reduces lung virus
replication. BALB/c mice were immunized twice two weeks apart with
10 mg of Alhydrogel-adjuvanted PBS, VLP-1123, VLP-1632, VLP-1818 or
VLP-1965. Two weeks after the boost, mice were challenged with 4 LD50
of X47 virus. Six days after challenge, four (PBS) or five (all other groups)
mice from each group were sacrificed to determine lung virus titers.
Virus titers are expressed as mean log10 TCID50/ml and error bars depict
the standard error of the mean.
doi:10.1371/journal.pone.0059081.g006
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been immunized twice with 10 mg of Alhydrogel-adjuvanted
control (PBS, VLP-1123 or VLP-1632) or M2e-substituted VLPs
(VLP-1818 or VLP-1965) and challenged with 4 LD50 of X47
virus. However, there was no significant difference in lung virus
titer between mice vaccinated with VLP-1965 or with VLP-1818.
Cellular Immune Responses Following Challenge
We recently reported that M2e-immune mice that are
challenged with a sublethal dose of X47 virus mount cellular
immune responses against the viral nucleoprotein (NP). These NP-
specific T-cell responses were similar in magnitude to those in
challenged naı¨ve mice [35]. Therefore, we determined the M2e-
and NP-specific T cell responses in splenocytes isolated six days
after X47 challenge. An IFN-c specific ELISPOT analysis of
splenocytes stimulated in vitro with M2e peptide showed that after
challenge, VLP-1965 immunized mice had significantly stronger
cellular responses than VLP-1818 immunized mice (Fig. 7A).
These responses were presumable due to the activation of CD4+
T-cells [31]. However, this result should be interpreted with care
because these M2e-specific T cell responses include those induced
by vaccination in the VLP-1818 and VLP-1965 immunized mice
as well as those induced by the influenza A virus challenge. IFN-c
specific ELISPOT analysis revealed comparable NP-specific
responses in splenocytes from all mice, even though M2e-immune
mice were protected from challenge whereas control mice died
(Figure 7A).
Discussion
We describe the use of VLP-1965, an improved M2e-based
universal influenza A vaccine candidate, and compare its
properties and efficacy to the previously reported VLP-1818
[44]. The carboxy-terminus of VLP-1965 comprises part of the
arginine-rich domain of HBc (amino acid residues 150–163),
allowing these particles to trap nucleic acids. Immunization with
Figure 7. Cellular immune responses and histopathology following challenge.Mice were immunized as described in the legend of Figure 6.
A. Six days after challenging the mice with 4 LD50 of X47 virus, four (PBS) or five (all other groups) mice from each group were sacrificed to prepare
splenocytes. IFN-c responses after M2e (top) or NP (bottom) peptide restimulation were determined by ELISPOT analysis. Bars represent the average
number of spots determined for individual mice (analyzed in triplicate) from each group. Error bars represent standard error of the mean. (*:P,0.05).
B. Representative hematoxylin-eosin stained lung tissue section prepared on day four after challenge of mice immunized with 10 mg of Alhydrogel-
adjuvanted VLP-1632, VLP-1818 or VLP-1965. VLP-1123 (a): diffuse presence of a pronounced interstitial, alveolar (*) and bronchiolar (arrow) mixed
inflammatory infiltrate interlaced with necrotic debris. VLP-1818 (b): focal presence of a limited mixed inflammatory infiltrate both in the interstitial,
alveolar (*) as well as bronchiolar (arrow) structures. VLP-1965 (c): Some congestion, but no inflammatory reaction.
doi:10.1371/journal.pone.0059081.g007
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either of these M2e-displaying VLPs protected mice from death
from a potentially lethal influenza A virus challenge. Furthermore,
after challenge, M2e-VLP immunized mice displayed less histo-
pathological abnormalities than control-VLP-immunized mice:
the alveolar structure was less affected, and alveolar pathology was
more focal (Figure 7B). However, immunization with M2e-
displaying VLPs harboring the RNA-binding domain (VLP-
1965) protected better against weight loss following challenge
than immunization with VLPs lacking this domain (VLP-1818). In
contrast, immunization with the control VLPs did not protect and
did not result in a difference in morbidity in mice immunized with
either control VLP. This indicates that the reduction in morbidity
was due to induction of an adaptive immune response against the
M2e-antigen and not to the induction of inflammation. Lung virus
titers were lower in M2e-immunized mice compared to the
controls whereas viral loads determined on day six after challenge
were comparable in the VLP-1818 and VLP-1965 immunized
mice. This may be explained by the lack of in vitro neutralizing
activity of M2e-specific IgG [35]. In addition, a difference in
morbidity does not necessarily correlate with a difference in lung
virus load in the mouse model for influenza [50].
M2e-based protection against influenza can be mediated by
M2e-specific antibodies but might also depend on M2e-specific
CD4 T cells [31]. M2e-specific IgG protects mice from influenza
infections by a mechanism that involves both Fcc receptors and
alveolar macrophages [32]. As M2e-specific antibodies probably
cannot readily bind to influenza particles, it is likely that M2e-
specific antibodies protect against infection by eliminating the
infected cells via ADCC or phagocytosis. We previously demon-
strated that M2e-specific IgG2a antibodies can protect against
influenza infections more efficiently than M2e-specific IgG1
antibodies. In addition, M2e-specific IgG1 failed to protect Fcc
receptor III knockout mice, but M2e-specific IgG2a could rescue
protection in these animals [32]. Vaccination with M2e-VLPs
harbouring the RNA-binding domain induces higher levels of
M2e-specific IgG2a antibodies. In this way, the enhanced
protection triggered by immunization with M2e-VLPs harboring
an RNA-binding domain might be explained by the enhanced
induction of IgG2a antibodies. So by promoting the induction of
M2e-specific IgG2a antibodies, VLP-1965 could promote Fcc-
receptor-mediated elimination of infected cells, thereby further
limiting inflammation and morbidity.
Following immunization, nucleic acids bound within VLP-1965
are presumably taken up by antigen-presenting cells. The
vertebrate innate immune system is armed with both extracellular
and intracellular molecular sensors that recognize pathogen-
associated molecular patterns such as unmethylated CpG DNA
and single- and double-stranded RNA [51]. Triggering of these
sensors, e.g. the Toll-like receptors TLR-3, -7, -8 and -9 by nucleic
acids induces a signaling cascade that leads to the expression of
several cytokines. These in turn activate the innate immune
system, which then programs a specific immune response. Riedl
et al. demonstrated that deleting the Arg-rich C-terminus of HBc
results in particles of 149-aa that retain less than 2% of the RNA
binding capacity of full-length HBc [43]. This reduced RNA
binding correlated with an IgG-isotype switch from the induction
of a predominantly Th1 response with high IgG2a titers (upon
vaccination with full-length HBc) towards a Th2 response with
high HBc-specific IgG1 antibody titers (upon vaccination with
truncated HBc-149 lacking nucleic acids) [43]. VLP-1965
combines three tandem M2e repeats presented at high density
on its surface and entraps nucleic acids. Most likely, these nucleic
acids (presumably bacterial RNA) bias the M2e-specific immune
response towards a Th1-type, as evidenced by the enhancement of
the serum titer of anti-M2e IgG2a. A major Th1-type cytokine is
IFN-c. Indeed, based on our ELISPOT data, M2e-specific T cell
responses resulting in IFN-c production were increased in the
spleen of VLP-1965 immunized mice. In addition, we compared
IL-6 and IL-1b mRNA levels induced by in vitro stimulation of
differentiated dendritic cells derived from TRIF2/2, MyD882/2
and WT mice with VLP-1632 or VLP-1965. In the absence of
MyD88 and to a lesser extent of TRIF, the induction of these pro-
inflammatory genes was strongly diminished, suggesting the
involvement of Toll-like receptors in costimulation. Interestingly,
bacterial mRNA co-administered with bacterial antigens, acts as
a pathogen-associated molecular pattern that promotes humoral
responses, including switching of antibody isotype classes [52].
M2e-specific IgG2a antibodies play an important role in the
protection induced by the M2e-vaccine against influenza [32,46].
These findings are corroborated by the improved protection
obtained with VLP-1965 relative to VLP-1818. In addition, we
recently demonstrated that M2e-specific IgG1 failed to protect
Fcc-receptor III knockout mice, and that M2e-specific IgG2a
could rescue protection in these animals [32]. An important role
for IgG2a antibodies in protection against influenza has also been
demonstrated in SCID mice by passive immunization with anti-
M2e IgG monoclonal antibodies [32,53].
Conventional influenza vaccines hamper the development of
heterosubtypic immunity endowed by T-cells [35]. Such T cell
responses are induced by natural infection with influenza viruses
and many of these responses are cross-protective because they are
mainly directed against conserved internal structural proteins.
Following infection with influenza A virus, M2e-immune mice
mount cytotoxic T cell responses directed against NP and HA that
are comparable to those in sham-vaccinated mice, as we recently
reported in a study involving the VLP-1818 vaccine antigen [35].
It was beyond the scope of the current work to extensively
compare such T cell responses in challenged mice that had either
been vaccinated with either VLP-1818 or the Th1-biasing VLP-
1965 vaccine, but nevertheless we found that the latter particles
did not compromise the T cell responses directed against NP
(Figure 7).
VLP-1965 was recently evaluated successfully in a Phase I
clinical study to document its safety and immunogenicity in
humans (ClinicalTrials.gov, Identifier NCT00819013). The M2e-
vaccine remains a valid pandemic influenza vaccine candidate and
also holds promise as a vaccine that could be used in young
children to control disease without compromising T cell immunity
upon exposure to seasonal or pandemic influenza [35]. Alterna-
tively, the M2e-vaccine could be used as an adjunct of the
currently licensed influenza vaccines to broaden their protective
efficacy [34]. VLP-1965 is a promising candidate for such
strategies.
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